7th November 2016
Innovative biotechnology company, Axim Biotechnologies Inc has appointed Grayling in the US to support its Investor Relations and Public Relations’ needs.
Axim Biotechnologies is engaged in the research and development, and production of pharmaceutical, nutriceutical and cosmetic products, as well as the procurement of genetically and nano-controlled active ingredients. The company’s particular focus is on the development of treatments for pain, spasticity, anxiety and other medical disorders using cannabinoids-based products. Pharmaceutical R&D aims to deliver systems and active pharmaceutical ingredients for treating conditions such as Parkinson's disease, Alzheimer's disease, restless leg syndrome and Crohn's disease.
Presently, the company is conducting clinical studies of MedChewRx, a pharmaceutical chewing gum containing cannabinoids. The company is in the process of getting FDA and EMA regulatory approval to launch this product in 2017, and it is in regard to this that Grayling is providing support.
Grayling’s efforts will be driven by New York based executive vice president, Lucia Domville. She says: “This is a fascinating company that is really pushing the boundaries with its research, and we are thrilled to be their partner.”
21st November 2017
New Affiliates Extend LatAm Network
Grayling has extended its Latin American reach, with the signing of a new strategic alliance with the agency Mazicorp SpA, which operates in Chile and Peru.With this new agreement, Grayling...Read More
10th November 2017
Digital Award Win for Grayling
Grayling this week picked up a PR News Digital Award in the 'Location-Based Digital' category, for its work with VAIO. The 'Taking a Bite Out of the Big Apple' campaign targeted...Read More
9th November 2017
Top Technology Companies Choose Grayling
Two Grayling clients have made it on to the prestigious Deloitte Technology Fast 500 list, which identifies the fastest growing technology companies in North America. Education tech firm, Course Hero,...Read More